^
Association details:
| Biomarker: | CTLA4 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
216P - Relationship between regulatory T lymphocytes (Treg) - related genes and pathological response to neoadjuvant docetaxel - carboplatin in early-stage Triple Negative Breast Cancer (TNBC)
Published date:
12/01/2022
Excerpt:
Within a prospective multicenter study, we analyzed 221 pre-treatment FFPE tumor samples from patients with TNBC who had received neoadjuvant docetaxel-carboplatin….5 genes presented a higher expression in responders vs. non-responders in multivariable analysis: FOXP3 (p = 0.04), CTLA4 (p = 0.005), CD4 (p = 0.013), CD274 (p = 0.03), and FCRL1 (p = 0.019).
